ViGenCell Inc.

ViGenCell Inc. is a South Korean biotechnology company that provides immune cell therapies. Its pipeline includes ViTier, an antigen-specific killer T cell therapy with candidates such as VT-EBV-N for NK/T lymphoma and VT-Tri(1)-A for AML; ViMedier, a cord blood-derived myeloid suppressor cell therapy including VM-GD for GvHD and VM-AD for atopic dermatitis; and ViRanger, an off-the-shelf allogeneic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia. The company was founded in 2013 and is based in Seoul, South Korea.